Compare Neurocrine Biosciences Inc (NBIX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SYSCO Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while SYSCO Corporation trades at $81.58 (market cap $38.25B). The key difference: SYSCO Corporation is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and SYSCO Corporation pays a 2.76% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SYY | |
|---|---|---|
Market Cap | $15.77B | $38.25B |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $91.16 |
52-Week Low | $123.10 | $69.30 |
Enterprise Value | $15.78B | $51.43B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Sysco Corporation (SYY) trades at $79.84, down 0.26% with a bullish technical signal despite mixed moving averages. The company reported $81.37B in revenue for 2025 with a 2.08% net margin and maintains strong analyst support with 60% buy ratings. Recent news highlights AI efficiency initiatives and reaffirmed 2027 guidance, while the pending Jetro Restaurant Depot acquisition presents both growth opportunities and integration risks.
Sysco offers stable fundamentals with consistent revenue growth and dividend aristocrat status, but faces execution risks from its major acquisition and margin pressures. The stock trades below the $88.25 consensus target, suggesting potential upside if AI efficiency gains materialize and integration proceeds smoothly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
